The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: A population-based study

BJU International

Volumn 114, Issue 6, 2014, Pages E82-E89

  Gandaglia, Giorgio ^a   Sun, Maxine ^a   Popa, Ioana ^a   Schiffmann, Jonas ^a   Abdollah, Firas ^b   Trinh, Quoc Dien ^d   Saad, Fred ^a   Graefen, Markus ^c   Briganti, Alberto ^b   Montorsi, Francesco ^b   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

androgen deprivation therapy; cardiovascular events; prostate cancer; side effects

Indexed keywords

GONADORELIN AGONIST; ANTIANDROGEN; GONADORELIN;

ACUTE HEART INFARCTION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; POPULATION RESEARCH; PROPENSITY SCORE; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; RISK ASSESSMENT; SOCIAL STATUS; SUDDEN CARDIAC DEATH; SURVIVAL RATE; UNITED STATES; AGONISTS; CANCER REGISTRY; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; MYOCARDIAL INFARCTION; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR;

AGED; ANDROGEN ANTAGONISTS; COHORT STUDIES; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MYOCARDIAL INFARCTION; ORCHIECTOMY; PROPENSITY SCORE; PROSTATIC NEOPLASMS; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 84920140855     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12732     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
2. Sharifi N, Gulley JL, Dahut WL,. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244
3. Gilbert SM, Kuo YF, Shahinian VB,. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol 2011; 29: 647-653
4. Heidenreich A, Bastian PJ, Bellmunt J, etal. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-479
5. Bolla M, Van Tienhoven G, Warde P, etal. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-1073
6. Messing EM, Manola J, Yao J, etal. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479
7. Conteduca V, Di Lorenzo G, Tartarone A, Aieta M,. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Oncol Hematol 2013; 86: 42-51
8. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 2013; 64: 159-166
9. Gandaglia G, Sun M, Hu JC, etal. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol 2014 [Epub ahead of print]. doi: 10.1016/j.eururo.2014.01.026
10. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456
11. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46
12. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J,. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014; 65: 565-573
13. Jespersen CG, Norgaard M, Borre M,. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014; 65: 704-709
14. Wong YN, Mitra N, Hudes G, etal. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006; 296: 2683-2693
15. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-1267
16. Hu JC, Gu X, Lipsitz SR, etal. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009; 302: 1557-1564
17. D'Agostino RB Jr,. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281
18. Ho DE, Imai K, King G, Stuart E,. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011; 42
19. Rosario DJ, Bourke L, Keating NL,. Androgen deprivation therapy and cardiovascular harm: are all men created equal? Eur Urol 2014; 65: 574-576
20. Van Hemelrijck M, Garmo H, Holmberg L, etal. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 2010; 28: 3448-3456
21. Nguyen PL, Je Y, Schutz FA, etal. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306: 2359-2366
22. Lu-Yao GL, Albertsen PC, Moore DF, etal. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-181
23. Bolla M, Gonzalez D, Warde P, etal. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300
24. Denham JW, Steigler A, Lamb DS, etal. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451-459
25. Klotz L, Boccon-Gibod L, Shore ND, etal. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-1538
26. Saylor PJ, Keating NL, Smith MR,. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 2009; 24 (Suppl. 2): S389-394
27. Smith MR, Finkelstein JS, McGovern FJ, etal. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603
28. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C,. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104: 195-201
29. Fahed AC, Gholmieh JM, Azar ST,. Connecting the lines between hypogonadism and atherosclerosis. Int J Endocrinol 2012; 1-12
30. Liu PY, Death AK, Handelsman DJ,. Androgens and cardiovascular disease. Endocr Rev 2003; 24: 313-340
31. Chen HF, Jeung EB, Stephenson M, Leung PC,. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999; 84: 743-750
32. Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bouloux PM,. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 2005; 142: 103-110